MEI/Kyowa Kirin Show More Data Supporting Zandelisib’s Safety Profile

 
• By Alaric DeArment

Presentations at EHA show the drug has a favorable safety profile compared with other PI3K-delta inhibitors alone and in combination with Rituxan, plus strong efficacy.

MEI and Kyowa Kirin presented data at EHA for the PI3K-delta inhibitor zandelisib • Source: Shutterstock

More from Clinical Trials

More from R&D